

INDEX

A

- AAVs. *See* Adeno-associated viruses
- AcMNPV. *See* *Autographa californica* multicapsid nucleopolyhedrosis viruses
- Active pharmaceutical ingredient (API)..... 472, 476, 477, 482
- Active-specific immunization (ASI), NDV
 delayed type hypersensitivity (DTH)
 response 578
 efficiency of 591
 postoperative studies 588
- Adeno-associated viruses (AAVs)..... 448
 advantages and drawbacks 451
 replication and expression..... 449–450
- Adenosine deaminase deficiency—severe combined immunodeficiency (ADA–SCID) 9
- Adenoviral vector designing
 biodistribution selectivity
 Ad5 erythrocyte 61
 cells and receptors 60
 sinusoidal fenestrations 59
 viral uptake 61
 capsid proteins 57–58
 efficacy mutations
 adenovirus death protein (ADP) and 69
 E3 mutant 70
 oncolytic potency 67–68
 plaque assay 68
 gene therapy 58
 mutation-rescue selectivity
 CR1 and CR2 mutations 66–67
 E1B-55K 66
 protein translation 67
 serotype 58–59
 transcriptional selectivity
 capsid composition 64
 promoters 65
 transductional selectivity
 DNA transfer 62
 knob replacement 64
 triple mutation 63
 tumor-targeting peptides 63–64
 transgenes, immunocentrics and virocentrics
 chemotherapy and 71
 proponents 70
- Adenovirus death protein (ADP) 69, 70
- ADEPT. *See* Antibody-directed enzyme prodrug therapy
- Agarose gel electrophoresis (AGE) 92, 477–478, 489
 damaged plasmid 482
 in-process control (IPC) 479
 pCMV-luc plasmid 485
 plasmid form distribution 484
- AGE. *See* Agarose gel electrophoresis
- Aldehyde dehydrogenase (ALDH) 35
- Antiangiogenic cancer therapy 32–33
- Antibody-directed enzyme prodrug
 therapy 134
- Antigen-presenting cells (APCs) 33, 168, 196, 212, 245, 248, 249, 251
- Antisense oligonucleotides 352
- Antisense technology 351
- Antitumor DNA vaccines
 advantages 211–212
 cDNA cloning and immunization
 vector 213–214, 219–221
 construction 218–219
 disadvantages 212–213
 immunological efficacy evaluation
 antigen-specific antibody enzyme-linked immunosorbent-assay 230
 cytotoxic immune responses 231–232
 IFN γ secretion 230–231
 intradermal 217
 intradermal rodent immunizations 228–229
 Rodent Euthanasia and Spleen/
 Sera Harvest 229
 materials
 DNA construction 213–215
 immunological efficacy
 evaluation 217–218
 production and purification 216
 target antigen expression 215–216
 production and purification 226–227
 DNA analysis 228
 GigaPrep purifications 227–228
 target antigen expression
 cell lines transfection 223
 transcription confirmation 223–224
 translation confirmation 224–226
 vaccine construct confirmation 221–222

- Antitumor vaccination
clinical protocol 518
formulation 517
immune monitoring
local gene delivery 521–522
PCR analysis 523–524
T cell phenotyping 523
patient
eligibility 519–521
treatment 521
storage and preparation 518
APCs. *See* Antigen-presenting cells
API. *See* Active pharmaceutical ingredient
Arginine–glycine–aspartic acid (RGD) 57, 63, 64, 68
AS1411 364, 379, 380
Autographa californica multicausid nucleopolyhedrosis
viruses (AcMNPV) 450
Autologous tumor vaccine–newcastle disease
virus (ATV–NDV)
anti–HNxIL–2 594
bsHN–CD3 and bsHN–CD28 592
genetic engineering possibilities 597
granulocyte/macrophage colony–stimulating
factor (GM–CSF) gene 595
human parainfluenza virus type 3
(HPIV3) gene 597
reverse genetics 597
- B**
- Bacteria–directed enzyme prodrug therapy 134
Bacterial alkaline phosphatase 122
Bacterial backbone
DNA 99
sequence 101
Bacterial vectors development, tumor–targeted
gene therapy
advantages 132–133
bacteria–mediated delivery systems
administration routes 147–149
double expression 146
eukaryotic expression 144–146
gene delivery 140, 141
prokaryotic expression 144
therapeutic genes 146–147
tumor localization 143
tumor–targeting strains 140–141
virulent tumor–targeting strain 141–143
bacteria–mediated therapy
anti–angiogenic 137–138
cytokine gene 138–139
description 133–134
enzyme prodrug 134, 136–137
RNA interference 139–140
vector–mediated 135–136
gene delivery vectors 131–132
- Baculovirus expression vector systems 450
Ballistic transfer systems 197
BAP. *See* Bacterial alkaline phosphatase
BDEPT. *See* Bacteria–directed enzyme prodrug therapy
BEVS. *See* Baculovirus expression vector systems
Bicinchoninic acid (BCA) method 454, 464–465
Bioluminescence imaging technique
materials 637–638
in vivo screening 642–643
Bovine spongiform encephalopathy 411, 480
Brain tumor
phagocytic microglia role 77
treatments 76
oncolytic viral therapy
for medulloblastoma (MB) 615
UV–inactivated 614
Breast cancer
oncolytic viral therapy
tumor shrinkage and metastasis control 617
viral protein detection 615
HER2/NEU in 88
BSE. *See* Bovine spongiform encephalopathy
Buffers and enzyme assay systems
cytokines and transgenic protein
products assays 172
luciferase and hAAT assay 171
X–gal assay 171–172
- C**
- Cancer gene transfer (GT)/therapeutic clinical
research ethics 437–438
early phase
human clinical testing 426–427
phase 1 study 427–428
scientific model application 428
Gendicine 438–439
modest translational distance
equipoise 428
external and internal validity 430
maintenance 430–431
principles 429
public expectations 439–440
research–treatment, phase 1 trials
risk assessment implication 436
therapeutic value 435–436
translational studies 434–435
strategies of 87–88
studies and consent practices
therapeutic misconceptions 435, 437
therapeutic misestimations 436
studies and risk
agents 432–433
and bystanders 433–434
conventional regulatory response 433
invasive tissue biopsies 432

- uncertainty and
 - agents..... 426
 - antibiotic combination..... 425
 - interventions..... 425–426
 - viral oncolytic therapy..... 438
 - Cancer Therapy Evaluation Program (CTEP)..... 518
 - Capillary gel electrophoresis (CGE)..... 202, 472, 482–485
 - CAR. *See* Coxsackie and adenovirus receptor
 - CD34+ cells
 - engraftment potential..... 688
 - frozen sample selection..... 687–688
 - NOD/SCID mouse..... 684
 - prestimulation..... 670–671, 676
 - transduction..... 672–673, 676–678
 - Cell-based plaque assay, ONYX-015..... 707, 713
 - Cell viability (MTS) assay, vaccinia virus
 - materials..... 637
 - method..... 640–641
 - CGE. *See* Capillary gel electrophoresis
 - Chemogene therapy..... 302
 - Chemoprotection
 - colony assay
 - materials..... 673
 - method..... 678–679
 - cytokine combinations..... 668
 - drug relevant cellular pathways..... 663
 - drug-resistance gene transfer
 - gene(s) selection..... 662–665
 - materials..... 669–674
 - method selection..... 665–668
 - mouse models..... 668–669
 - myeloprotection..... 662, 664
 - flow cytometry
 - materials..... 674
 - methods..... 680
 - retroviral vector..... 665–666, 690–691
 - strategy and efficiency..... 652
 - suicide gene..... 667
 - Chemosensitization, tumor cells
 - cell culture..... 302–303
 - combination chemotherapy..... 301–302
 - electrophoretic mobility shift assay (EMSA)..... 303–304
 - nuclear factor- κ B (NF- κ B) DNA
 - binding activity
 - biotin-labeled DNA-binding band..... 309–311
 - cytoplasmic and nuclear protein extract..... 306–307
 - DNA-binding reaction..... 307–309
 - E2F-1 and doxorubicin..... 307, 310
 - NF- κ B reporter plasmid..... 303
 - pNF- κ B-Luc reporter plasmid..... 305–306
 - transfection efficiency..... 304–305
 - Chinese hamster ovary (CHO) cells..... 158, 215, 222, 223
 - CIOMS. *See* Council for International Organizations of Medical Sciences
 - CMV. *See* Cytomegalovirus
 - Colon cancer, oncolytic viral therapy
 - immunosuppression study..... 618
 - normal *vs.* cancer cell line..... 617
 - Council for International Organizations of Medical Sciences..... 438
 - Coxsackie and adenovirus receptor (CAR)..... 11, 60–61, 63, 69
 - CTEP. *See* Cancer Therapy Evaluation Program
 - CTLs. *See* Cytotoxic T lymphocytes
 - Current good manufacturing process (cGMP)..... 448
 - Cytomegalovirus (CMV)..... 62, 233, 261, 358
 - Cytosine deaminase (CD)
 - activity assay
 - materials..... 651
 - methods..... 652–653
 - antitumor effects..... 203
 - cloning and expression
 - materials..... 651
 - methods..... 652
 - TNF- α , 202
 - Cytotoxic T lymphocytes (CTLs)..... 213, 500, 502, 507
 - AG-specific and multimer binding analysis..... 256
 - CD107a translocation assay..... 256
 - non-radioactive CFSE-based assay..... 249, 254–256
- D**
- Delayed-type hypersensitivity (DTH)..... 505, 578
 - Dendritic cells (DCs)..... 138, 139, 233, 502–503, 574
 - description..... 245
 - immunity analysis..... 246–247
 - lentiviral transduction..... 250
 - modification of..... 245–246
 - and peripheral blood mononuclear cells preparation..... 247
 - phenotype analysis..... 250–251
 - preparation..... 249
 - Deoxyribonucleic acid (DNA)..... 545
 - Dihydrofolate reductase (DHFR) mutant..... 35
 - Downstream processing (DSP)..... 476, 481, 482
 - Doxorubicin..... 707, 711
 - Drug-resistance gene transfer, chemoprotection
 - chemotherapeutic resistance..... 662–664
 - cytokine combinations..... 668
 - drug relevant cellular pathways..... 663
 - gamma-retroviral transductions..... 688
 - materials
 - CD34+ cells preparation..... 670–671
 - colony assay and single-colony PCR..... 673–674
 - flow cytometry..... 674
 - lin⁺hematopoietic cells isolation..... 669–670
 - RetroNectin[®] coating..... 671–672
 - transduction..... 672–673

- Drug-resistance gene transfer, chemoprotection (*Continued*)
methods
 CD34+ cells prestimulation 676
 colony assay..... 678–679
 flow cytometry..... 680
 lin⁺ hematopoietic cells isolation..... 675–676
 RetroNectin[®] coating 676
 single-colony PCR..... 679–680
 transduction..... 676–678
 in vivo experimental models 681–684
mouse models 668–669
retroviral vector..... 665–666, 690–691
suicide gene 667
vector designs 665
- E**
- Electromobility shift assay (EMSA)..... 385–387,
 366–367, 370–372, 376
 and MTT assay 387
 radiolabeling and polyacrylamide gel
 electrophoresis 381–382
 binding reactions 308
 NF- κ B signaling..... 304–305
- Electroporation, gene transfer
 DNA injection and electric field pulses
 application 162
 effective DNA transfer 159
 materials 159–160
 model cell 157–158
 plasmid DNA preparation 160
 pulse protocols..... 161
 response monitoring 162
 target tissue preparation..... 160–162
- Enhanced green fluorescent protein (eGFP)..... 455
- Enzyme-linked immunosorbent
 assay (ELISA)..... 175, 522
- Epidermal growth factor receptor (EGFR)
 antisense orientation..... 339–340
 cell culture 338
 cell lines and transfection..... 336–337
 flow cytometry..... 337
 identification
 subcutaneous glioma model 344
 tumor growth..... 345
 immunohistochemistry 337–338
 RNA interference (RNAi) and 336
 SDS-PAGE..... 337
 siRNA and antisense constructs
 cell proliferation and invasion..... 342–344
 glioma cell growth 343
 immunofluorescence staining..... 341–342
 transfection 340–341
 Western blot analysis 341
 siRNA expression plasmid..... 338–339
 stripping and reprobing blots..... 337
 therapeutic modalities..... 335
 transwell invasion assay..... 338
 tumor cell sensitization 286, 288
 tumor samples, immunohistochemistry 346
- Epstein-Barr virus (EBV) 25
- Equine infectious anemia virus (EIAV) vectors 17
- Equipoise..... 428
- Escherichia coli*
 in vivo recombination 93
 LacZ gene 78, 82
 minicircle DNA..... 90
 site-specific recombinase 87, 92
- Eukaryotic expression cassette..... 90, 99, 101, 146
- F**
- Familial hypercholesterolemia (FH)..... 8
- FDA. *See* Food and Drug Administration
- FH. *See* Familial hypercholesterolemia
- 5-Fluorouracil (5FU) treatment,
 chemoprotection 686–687
- Folate receptor (FR) 14
- Food and Drug Administration (FDA)..... 433
- Frog Prince* (FP), transposons 106, 109
- G**
- GALV. *See* Gibbon ape leukemia virus
- Ganciclovir (GCV) gene therapy 9, 28, 530
- GBM. *See* Glioblastoma multiforme
- GCP. *See* Good clinical practice
- Gendicine 438–439
- Gene-directed enzyme prodrug therapy (GDEPT) 134
- Gene gun delivery systems, cancer vaccine
 buffers and enzyme assay systems..... 171–172
 DNA cartridges preparation, animal care
 and skin treatment 173
 DNA coating onto gold particles..... 172
 epidermis and dermis gene transfer 173–174
 gold particle preparations and DNA
 vectors..... 170–171
 Helios gene gun..... 169–170
 instrumentation 170
 reporter gene expression assay
 hAAT assay 174–175
 mouse lung metastasis assay..... 175
 tissue extraction and luciferase assay 174
 X-gal staining and cytokine assay 175
 skin care and treatment..... 171
- Gene therapy
 high-intensity focused ultrasound (HIFU) 180
 history
 genetic information..... 6
 gene transfer 7
 geographical distribution 10
 hematopoietic stem cells (HSCs)..... 9–10
 monogenic recessive disorders 10–11

T cells, ADA gene expression.....	8
vectors development <i>in vivo</i>	7
X-linked-severe combined immunodeficiency (SCID-X1).....	8–9
host response	
antiangiogenic cancer therapy.....	32–33
immunotherapy.....	33–35
oncolytic viruses.....	29–30
newcastle disease virus.....	30
ONYX-015, 29	
posttranscriptional gene silencing.....	31–32
radioinducible to chemoinducible.....	30–31
suicide gene therapy.....	28–29
herpes simplex virus thymidine kinase (HSV-tk).....	28–29
transcriptional targeting.....	29
tumor suppressors	
p53.....	26–27
radiotherapy and chemotherapy.....	28
retroviral and adenoviral vectors.....	27
ultrasound-mediated gene transfection.....	181
vectors and delivery systems	
bacterial.....	25–26
nonviral.....	22–25
viral.....	11–22
GFP. <i>See</i> Green fluorescence protein	
Gibbon ape leukemia virus.....	552
dose response assay.....	554, 561
GALV <i>env</i> R-gene cloning.....	558–559
GigaPrep purification.....	216, 227–228
Glial fibrillary acidic protein (GFAP).....	346
Glioblastoma multiforme (GBM), HSV-tk/IL-2 gene therapy	
adventitious viral infections.....	534
antitumor activity evaluation.....	542
antitumor effect of.....	530
biological samples.....	535–536
clinical protocol.....	530
cytokine gene expression.....	536–537
design and objectives.....	531
ELISA cytokine production.....	537–538
endotoxin production.....	534–535
immunofluorescence staining.....	537
immunohistochemistry.....	537
master cell bank (MCB).....	531–532
patient selection	
eligibility criteria.....	538
exclusion criteria.....	538–539
replication-competent retroviral particles.....	535
retroviral vector-producing cells (RVPCs)	
for administration.....	539
ganciclovir administration.....	540
injection, surgical procedures.....	540
treatment schedule.....	539
safety assessment	
biological safety.....	541–542
clinical evaluation and laboratory analyses.....	540–541
side effects.....	541
sterility testing.....	533
treatment immune response	
cytokine expression, ELISA and quantitative RT-PCR.....	544
hematoxylin–eosin staining.....	543–544
tumor cell transduction <i>in vivo</i>	
immunofluorescence staining, HSV-TK gene expression.....	543
real-time RT-PCR, hIL-2 and HSV-TK gene expression.....	542–543
working cell bank (WCB).....	531–535
Glutathione S-transferase (GST)	
β -catenin proteins.....	365, 372
pull-down RNA binding assay.....	366, 370–371
recombinant proteins, preparation.....	368
Good clinical practice (GCP).....	397, 403, 530
Good laboratory practice (GLP)	
principles.....	397
regulations.....	407
Good manufacturing practice (GMP).....	530
principles.....	397, 410
procedures.....	412
quality and safety.....	409
requirements.....	411
G-quadruplex analysis.....	388–390
Granulocyte-macrophage colony-stimulating factor (GM-CSF).....	138, 503, 506, 507, 595–596
Green fluorescent protein (GFP).....	145, 199
G-rich oligonucleotides (GROs)	
cell culture and MTT assay.....	381
cells treatment.....	383
electrophoretic mobility shift assay.....	385–387
G-quadruplex analysis.....	388–390
limitation.....	380
MTT assay.....	383–384
oligonucleotides.....	381–383
oligomers radiolabeling.....	384–385
radiolabeling and polyacrylamide gel electrophoresis.....	381–382
stability assay.....	387–388
GST. <i>See</i> Glutathione S-transferase	
H	
Helios gene gun device.....	169
Hemagglutinin–neuraminidase (HN) protein, NDV	
cytotoxic T cell response.....	575
serine and functional activity.....	579
Hematopoietic stem cells (HSCs).....	34, 665, 667

- Herpes simplex virus (HSV)
 advantages..... 76
 cancer treatments..... 76
 materials required 77–79
 methods
 brain, virus extraction..... 82
 organotypic brain slices..... 79–80
 prostate organ cultures 81–82
 virus titration 83
 organotypic brain slices
 culture and preparation 79–80
 drug treatment and virus infection..... 80
 preparation of 77, 79
 tumor establishment 77, 80
 tumor-based therapies 75
 type-1..... 75, 551
 vectors..... 19
- Herpes simplex virus thymidine kinase (HSV-tk)..... 9, 28
- High-intensity focused ultrasound (HIFU)..... 180
- Histone at lysine 9 (H3K9me) 100
- Human immunodeficiency virus (HIV)..... 449, 538
- Human papilloma virus (HPV)..... 88
- Hypoxanthine phosphoribosyltransferase (HPRT)..... 7
- Hypoxia-inducible factor (HIF) 147
- I**
- ICAM. *See* Intercellular adhesion molecule
- Immune modulation, NDV
 adaptive immunity
 dendritic cells (DCs) stimulation..... 574–575
 T lymphocytes and cytolytic activity..... 575–576
 innate immunity
 macrophage and monocyte activation..... 573
 natural killer (NK) cell activation 572–573
 interferon (IFN) response..... 577–579
- Immunoblotting technique. *See* Sodium dodecyl sulfate polyacrylamide gel electrophoresis
- Immunotherapy
 active..... 33–34
 adoptive 34
 normal cells protection 34–35
- IND. *See* Investigational new drug
- Institutional review boards (IRBs)..... 428
- Intercellular adhesion molecule (ICAM)..... 246
- Interferon-induced genes (ISG) 570
- Internal ribosomal entry site (IRES) 65, 233
- Inverted terminal repeats (ITRs)..... 65
- Investigational New Drug (IND)
 amendments 417
 applications..... 398, 400
 meeting process 402
- IRBs. *See* Institutional review boards
- IRES. *See* Internal ribosomal entry site
- ITRs. *See* Inverted terminal repeats
- K**
- Kupffer cells..... 60–62
- L**
- LacZ gene expression 200
- Lentiviral vector-modified dendritic cells
 allogeneic mixed lymphocyte reaction 248, 252
 antigen-specific effector functions analysis
 AG-specific T cell..... 254
 CD107a translocation assay..... 256
 CTL assay..... 254–256
 multimer binding..... 256
 proliferation 253–254
 antigen-specific T cells 248, 253
 antigen uptake function
 analysis..... 251
 assay 248
 CFSE-based CTL assay 249
 DC phenotype analysis..... 250–251
 encoding immune modulatory genes 250
 flow cytometry analysis..... 248
 intracellular cytokines 248
 lentiviral preparation and transduction 247–250
 multimer binding analyses 249
 and peripheral blood mononuclear
 cell preparation 247
- Lentiviral vectors (LVs)
 immune-modulatory genes encoding 246
 preparation..... 250
- Lewis lung carcinoma (LLC) cells 290, 291, 294, 296
- Limulus amoebocyte lysate (LAL) 534
- Long-term gene transfer, transposable elements
 cancer gene therapy
 PEI/DNA complex..... 109–110
 SB-mediated delivery 109
 nonviral delivery vectors
 DNA vector configurations 107
 integration and..... 108–109
 retroviral and lentiviral..... 105
 SB-mediated chromosomal integration 107
 transposons 106
 subcutaneous murine tumors
 anesthetize mice..... 111–112
 intratumoral injection 111, 112
 PEI/DNA complex preparation 110–111
- Low-density lipoprotein (LDL)
 receptor gene..... 8
- Low-volume multiuse nozzle
 jet-injection systems..... 197–199
- L523S, lung cancer antigen 500, 503, 507
- Lucanix™, allogeneic vaccine..... 502–503
- Luciferase enzyme, viral labelling 645–646
- Lung cancer, oncolytic viral therapy. *See* Oncolytic viral therapy, reovirus

M

Macugen, aptamer drug..... 364

Major histocompatibility complex (MHC).....212, 245, 246

Master cell bank (MCB) 413, 531

MCP. *See* Monocyte chemoattractant protein

MCS. *See* Multiple cloning site

MDR. *See* Multidrug resistance

Membrane electroporation (MEP)..... 157

Messenger RNA (mRNA) 93

O⁶-Methylguanine-DNA-methyltransferase (MGMT) 685-686

MHC. *See* Major histocompatibility complex

Minicircle (MC) plasmid DNA

- description 87
- gene transfer efficiencies 88
- purification 93-94
- site-specific recombination
 - dimeric form 90-91
 - multimer resolution system 92
 - ParA resolvase system 91
- stringent control 92
- specific tumor antigens 88
- transgenes expression
 - advantages of 99
 - IFN γ production 99-101
 - plasmid-encoded gene 98
 - size and structure 98-99
 - structures 100
- vectors molecules, gene transfer
 - carcinoma cells 97
 - expression level comparison 95-96
 - gene transfer efficiency 98
 - transgene expression levels 94

Mitomycin-C 711

MOI. *See* Multiplicities of infection

Monocyte chemoattractant protein (MCP) 28

MTT assay

- and cell culture 381
- and competition EMSA 387
- methods 383-384

Multidrug resistance (MDR) 301, 302

Multiple cloning site (MCS)..... 221

Multiplicities of infection (MOI)..... 517

Myeloprotection. *See* Drug-resistance gene transfer, chemoprotection

N

Nasopharyngeal carcinoma (NPC)..... 97

Natural killer (NK) cells 9, 89

Near-infrared (NIR) imaging.....292, 294, 296

Neomycin resistance gene (*NeoR*)..... 531

Newcastle disease virus (NDV)

- anti-HNxIL-2 594

- antineoplastic properties 567
- autologous tumor vaccine (ATV-NDV)..... 583
- bsHN-CD3 and bsHN-CD28 592-593
- cancer vaccine, rationale
 - animal tumor model study 584-585
 - ATV-NDV *vs.* ATV-Bacille Calmette-Guérin (BCG) 589
 - autologous tumor vaccine (ATV-NDV) 583
 - delayed type hypersensitivity (DTH)..... 578
 - human tumor cell study 585
 - nonrandomized pilot studies..... 591
 - quality and efficacy criteria 589
 - survival advantages..... 587
 - tumor-associated antigens (TAAs) 583
 - tumor neutralization assay (TNA)..... 586
- characteristics 595
- classification and structure..... 566
- genetic engineering possibilities 597
- GM-CSF gene 595
- human application and safety
 - administration routes 581
 - clinical studies..... 582
 - dose-limiting toxicities 581
 - metastatic tumor 582
- human parainfluenza virus type 3 (HPIV3) gene 597
- mechanism
 - antiviral defence responses..... 571
 - danger signals (DS) 577
 - HLA molecule upregulation..... 576
 - immune modulation 572-580
 - infection and replication
 - interferon-induced genes (ISG) stimulation 570
 - oncolytic properties..... 571-572
 - retinoic acid-inducible gene (RIG-I)..... 578
 - toll-like receptor (TLR) system 576-577
 - tumor selectivity..... 569-571
- oncolytic properties
 - lytic and non-lytic strains 571
 - monocyclic *vs.* multicyclic replication 570
 - MTH68/H strain 572
- pathogenicity 580-581
- pharmacokinetics 580
- reverse genetics 597
- RNA viruses and interferon system 566
- viral xenogenization 575

Non-small cell lung cancer (NSCLC)

- B7.1 gene vaccine 507-508
- cancer patients and immunity
 - dendritic cells (DCs)..... 502
 - TIL and 501-502
 - tumor cells 501
- current therapy
 - bevacizumab 501
 - cytotoxic therapies 500-501

- Non-small cell lung cancer (NSCLC) (*Continued*)
 $\alpha(1,3)$ -galactosyltransferase..... 508–509
 GM-CSF gene-based vaccine
 adverse events 506
 dosage 503–505
 GVAX[®], 505
 tumor cells 506–507
 L523S gene vaccine 507
 T cells and 499–500
 TGF- β 2 antisense gene vaccine
 dosage 503
 Lucanix[™] 502–503
 side effects 504
- Nonsteroidal anti-inflammatory
 drugs (NSAIDs) 364
- Nonviral delivery systems
 cationic and nanoparticles polymers 24–25
 cationic lipids 23–24
 naked DNA 23
- Nonviral gene transfer, applications 89
- Nonviral jet-injection technology, naked DNA
 application, *in vivo*
 antitumoral gene therapy 202–203
 intratumoral 199–200
 stability analysis 202
 transgene expression analysis 200–202
 description 195–196
 clinical application 204–205
 in vivo gene transfer 197
 low-volume jet injection 197–199
 usage 196–197
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs
- Nuclear factor- κ B (NF- κ B)
 DNA-binding activity 306–311
 reporter plasmid 303
 signaling 304–305
- Nuclease resistance. *See* Stability assay
- O**
- Oligodeoxynucleotides
 cells treatment 383
 resuspension, concentration,
 and sterilization 382–383
- Oncolytic HSV vector
 GALV dose response assay 554, 561
 HSV-1, shuttle plasmids recombination
 homologous recombination transfections 560
 infected cellular DNA extraction 559
 linearization of 559–560
 viral recombinants purification 560–561
- OncoVEX strain
 derivation 555
 plaque morphology comparison 556
 prodrug activation 557
- prodrug assay 554, 561–562
production 554–557
therapeutic genes cloning 553
 Fcy::Fur gene 559
 GALV *env* R-Gene 558–559
transfection reagents 553–554
viral infected and shuttle plasmid
 DNA preparation 553
viral recombinants purification 554
- Oncolytic vaccinia strain
 materials 637–638
 methods
 design and construct 638–639
 in vitro selectivity testing 640–641
 in vivo screening, bioluminescence
 imaging 642–643
 virulence genes and tumor-targeting
 potential 636
- Oncolytic viral therapy, reovirus
 brain tumours
 live and dead (UV-inactivated)
 viral treatment 614
 medulloblastoma (MB), evaluation 615
 breast cancer
 tumor shrinkage and metastasis control 617
 viral protein detection 615
 chemotherapy combination 621–622
 colon cancer
 immunosuppression study 618
 normal *vs.* cancer cell line 617
 haematological cancer
 Burkitt's lymphoma cell lines sensitivity 620
 childhood sarcoma cell lines 621
 multiple myeloma and mantle
 cell lymphoma 620–621
 lung cancer 620
 ovarian cancer and cytopathic effect 618
 pancreatic cancer 619
 prostate cancer 618
 radiation therapy combination 621–622
 transitional cell carcinoma (TCC) 619
- Oncolytic viruses (OVs) 75
- OncoVEX
 derivation 555
 OncoVEX^{CD} prodrug activation 557
 and plaque morphology comparison 556
- ONYX-015 virus and chemotherapy
 combinational therapy
 cisplatin chemotherapy 706
 clinical trial methods
 dose-limiting toxicity (DLT) 712
 inclusion and exclusion criteria 708
 pretreatment evaluation/
 follow-up studies 708–709
 response criteria 712

study drug.....	709	Plasmid DNA vectors	
treatment schedule.....	709–711	covalently closed circular (ccc) form	472
laboratory analyses		dimensions.....	473
detection of.....	713	guidelines.....	471
immunohistochemistry.....	712–713	manufacture	
plasma neutralizing antibody titers.....	713	biomass concentration	480
tumor biopsies	714	cultivation parameters, determination.....	479
materials		cultivation process.....	481
p53 and viral infection.....	705–706	downstream processing.....	481–482
sarcomas	706–707	<i>Escherichia coli</i> host strains	478
synergistic activity response.....	706	large-scale	476
OptiCell 187–188		QC assays	477
Organotypic brain slices		quality control (QC) and quality	
culture and preparation.....	79	assurance (QA)	482–484
drug treatment and virus infection.....	80	minicircle (MC) technology.....	484–486
preparation of.....	77, 79	nonviral DNA vectors	
tumor establishment.....	77, 80	forms of.....	473–474
P		manufacturing process	475–482
Pancreatic cancer, oncolytic viral therapy.		quality profile.....	482–484
<i>See</i> Oncolytic viral therapy, reovirus		vaccination.....	474–475
Parental plasmid (PP).....	90	Plasmid vectors designing	
PBMC. <i>See</i> Peripheral blood mononuclear cells		bacterial plasmid replicon	
PCNA. <i>See</i> Proliferating cell nuclear antigen		multicopy status.....	118
PCR. <i>See</i> Polymerase chain reaction		stable.....	119
pCVD442-msbB vector construction, <i>Salmonella</i>		cloning strategies	
<i>typhimurium</i>		bacterial colony tests.....	122
materials	651	blunt DNA ends.....	124–126
method	654	chromosomal integration.....	121
pDNA. <i>See</i> plasmid DNA		cohesive DNA ends	123–124
PEDF. <i>See</i> Pigment epithelial-derived factor		replication-competent DNA species.....	126–127
Peripheral blood mononuclear cells (PBMC).....	522	restriction enzyme digestion	123
Phosphate-buffered saline (PBS)	535, 291, 292, 295	site-specific recombination	127
Phosphatidylserine (PS)	330	immune response.....	120–121
Phosphorodiamidate morpholino oligomers (PMO)		Kozak consensus sequence.....	120
cancer cells delivery		nonviral gene therapy.....	117–118
charged-based and unassisted.....	355	plasmid manipulation and propagation	121
scrape loading	354	plasmid marker	119
syringe loading.....	354–355	p-nitroaniline (pNA).....	535
cell culture and lysis.....	352–353	Polyacrylamide gel electrophoresis (PAGE).....	318
description	351	Polymerase chain reaction (PCR).....	59, 122,
plasmids.....	353	124, 127, 204, 262, 293, 295, 317, 319, 320,	
SDS-PAGE.....	353–354	365, 368, 370, 372–375, 408, 522, 533, 554.	
target protein		<i>See also</i> Antitumor vaccination	
detection of.....	357	Polytetrafluoroethylene (PTFE).....	77
MTT cell proliferation assay	356	Porcine parvovirus (PPV).....	534
photomicrography and plasmid based test.....	358	Prodrug assay.....	554, 561–562
propidium iodide staining.....	356	Proliferating cell nuclear antigen	
Western immunoblotting.....	356–357	(PCNA).....	304, 310, 311, 346
PI. <i>See</i> Propidium iodide		Propidium iodide (PI)	330, 331
PiggyBac transposons.....	108	Prostate cancer.....	618
Pigment epithelial-derived factor (PEDF).....	32	Prostate organ culture complete media	
Plaque assay, vaccinia virus		(POC-CM)	77–78
materials	637	Prostate organ cultures	
method	640	brain staining	
		HSV and microglia.....	81

- Prostate organ cultures (*Continued*)
- microglia immunofluorescence 82
 - oncolytic HSV β -galactosidase 82
 - oncolytic HSV extraction and titration 79
 - viral extraction 82
 - viral infection and spread 81
- Prostate-specific antigen (PSA)..... 287
- Protocol registration system (PRS)..... 405
- pSC65 plasmid, vaccinia virus 644–645
- Pulse repetition frequencies (PRF)..... 180
- Q**
- Quantitative polymerase chain reaction (q-PCR)..... 448, 454, 462–463, 468, 482
- R**
- Radiation-guided drug delivery systems
- adenovirus..... 288–289
 - antibody engineering 291
 - capsid coat 289
 - dosage..... 285–286
 - peptide prioritization 296–297
 - phage display 288
 - phosphate-buffered saline
 - and STE buffer 292
 - polyethylene glycol (PEG) 292
 - radiation targeting 287–288
 - stealth liposomes..... 289–290
 - T7 cloning 293
 - T7 phage preparation 293–294
 - tris-buffered saline 291–292
 - tumor cell sensitization strategy
 - p53 gene transfer 286–287
 - radiosensitization 286
 - suicide gene technology 287
 - tumor models and cell culture..... 291
 - in vivo* biopanning 294–295
- Radical oxygen intermediates (ROI) 30
- Randomized controlled trial (RCT) 425
- Relative light units (RLU)..... 184
- Renca tumor cells
- culture..... 319
 - mTRAIL protein production 328
 - PS externalization and PI exclusion..... 330
- Renilla luciferase..... 646
- Reovirus
- clinical trial, REOLYSIN..... 628–630
 - cured cells and acquired resistance 625–626
 - human disease
 - benign nature study..... 610
 - mild infections of..... 609
 - immune system 625
 - isolation and ideal attributes 608
 - oncolysis, molecular basis
 - apoptosis induction..... 613
 - Ras signalling and infectivity 611
 - replication 612
 - prototypical strains 609
 - purging effect
 - autologous stem cell transplants (ASCT) 622
 - ex vivo model system studies..... 623
 - small lymphocytic lymphoma (SLL) 624
 - toxicity studies 626–628
- Replication-competent lentiviruses (RCLs) 449
- Replication-competent retroviruses (RCRs) 29, 405, 531
- Retinoic acid-inducible gene (RIG-I) 578
- RetroNectin[®] coated plates
- materials 671–672
 - methods..... 676
- Retroviral vector, drug-resistance
- gene transfer 665–666, 690–691
- Retroviral vector-producing cells (RVPCs) 529
- Reverse transcriptase polymerase chain reaction (RT-PCR) 204
- RGD. *See* Arginine–glycine–aspartic acid
- Ribosomal RNA (rRNA) 534
- Ribosome-inactivating proteins (RIPs) 261
- RNA aptamers, cancer cell signaling
- DNA oligonucleotide library..... 365, 368
 - EMSA and 366–367, 371–372
- GST
- pull-down RNA binding assay..... 366, 370–371
 - recombinant proteins, preparation 368
- GST–TCF and GST– β -catenin..... 365
- immunoprecipitation 367, 373–375
- intramers construction 367, 371–372
- RT-PCR and real-time PCR..... 372–373
- SELEX and 363, 369–370
- stable aptamer transfectants, selection 375
- in vitro*
- selection 366, 369–370
 - transcription..... 365–366, 369
- Western blotting and immunoprecipitation..... 373
- Wnt/ β -catenin
- signaling..... 364
 - target gene 374
- RNA interference (RNAi)..... 31–32
- RNeasy[®] Mini Kit..... 536
- Rous sarcoma virus (RSV)..... 97
- RT-PCR. *See* Reverse transcriptase polymerase chain reaction
- S**
- Safety monitoring committee (SMC) 407
- Salmonella typhimurium*, tumor-selective therapy
- materials 651–652

methods	
CD activity assay	652–653
cytosine deaminase (CD), cloning and expression.....	652
pCVD442-msbB vector construction.....	654
<trc-cd<="" and="" cloning="" td="" transfer=""> <td>654–655</td> </trc-cd>	654–655
<i>MsbB</i> medium	651
tumor amplified protein expression therapy (TAPET)-cytosine deaminase (CD)	650
antitumor activity.....	656–657
¹⁴ C-5-Fluorocytosine (FC) and ¹⁴ C-5- Fluorouracil (FU), tissue distribution	657
quantification.....	656
VNP20009.....	649
Saporin suicide gene therapy	
cell culture	262, 267
cell lines and mouse strains.....	263
construction	
co-transfection assay	270–271
luciferase and bradford assay.....	271–272
MTT colorimetric assay	272–273
DNA complex formulation	
optimization.....	267–268
gel retardation assay.....	268–269
nuclease sensitivity assays	269
PEI/DNA relative N/P ratios.....	268
transient transfections.....	269–270
luciferase, bradford and MTT assay	264
nonviral transfections.....	263–264
pCI-SAP construct cytotoxicity	270
plasmid DNA preparation	
form SAP-KQ and bacteria	266
pCI-SAP expression vector	265
plasmids and molecular cloning reagents.....	263
<i>in vivo</i> studies	
intratumoral injection	274–277
melanoma B16F1 cells.....	273–274
nonviral vectors efficiency comparison.....	275
tumor growth, effects on.....	276
SDS-PAGE. <i>See</i> Sodium dodecyl sulfate- polyacrylamide gel electrophoresis	
SELEX. <i>See</i> Systemic evolution of ligands by exponential enrichment	
Severe combined immunodeficiency (SCID)	
adenosine deaminase-deficiency (ADA).....	8
SCID-X1.....	8
Simian virus 40 (SV40)	20–22
Single-colony PCR, chemoprotection	
materials	673–674
method	679–680
Small interfering RNA (siRNA)	88
SMC. <i>See</i> Safety monitoring committee	
Sodium dodecyl sulfate polyacrylamide gel electrophoresis	337, 448, 454–455, 464–465, 469
Sonotransfection	
<i>in vitro</i>	
HeLa cells, optimized.....	187
method	185–186
sonicating attached cells.....	186–187
<i>in vivo</i>	
intravisceral.....	189
in muscle.....	189–190
<i>in vivo</i> -simulated <i>in vitro</i>	
OptiCell.....	187–188
usage	188–189
Stability assay	
nuclease resistance	389
radiolabeling and polyacrylamide gel electrophoresis	381–382
Swiss-Injector.....	197–199
Systemic evolution of ligands by exponential enrichment.....	363, 369–370
T	
TAA. <i>See</i> Tumor-associated antigens	
Target antigen translation confirmation	
protein expression.....	225–226
protein preparation	224
SDS-PAGE.....	224–225
T cells	
detection	515
phenotyping.....	523
recombinant poxvirus development	516–517
Terminal deoxynucleotide transferase-mediated dUTP nick-end labeling (TUNEL).....	345, 346
Thymidine kinase gene, vaccinia virus.....	638, 644
TIL. <i>See</i> Tumor infiltrating lymphocytes	
Tissue culture infection dose (TCID)	461–462
T lymphocytes	575–576
TNF. <i>See</i> Tumor necrosis factor	
TNF-related apoptosis-inducing ligand (TRAIL).....	315
Toll-like receptors (TLRs).....	89, 576–577
TRAIL. <i>See</i> TNF-related apoptosis-inducing ligand	
Transduced bacterial plasmid DNA, production and purification.....	221
Transforming growth factor (TGF)-β	499, 500, 503, 504
Transitional cell carcinoma (TCC).....	619
Translating gene therapy	
clinical development	
data management plan.....	403
life-threatening disease	405
NIH guidelines.....	406–407
protocol elements.....	404
clinical trials planning strategy	
FDA guidances	402
goals and timelines.....	399
guidance documents	400–402

Translating gene therapy (<i>Continued</i>)	
drug and biological products principles	399
IND applications	398–399
manufacturing practices	
GMP principles	409–410
quality assurance	415
quality control testing	411
risk assessment	412
nonclinical development	
bioactivity studies	408
clinical parameters	407
toxicology testing	408–409
product-specific issues	415–416
quality control testing issues	
cell banks	413
mycoplasma	413
procedures	412
virus banks	414
regulation varies	398
US regulatory submissions	
clinical studies	416
FDA process	416–417
IND protocol and templates	418
patient sample testing	419
Transmissible spongiform	
encephalopathy (TSE)	480
Transposons	
gene therapy	107–108
integration	108
structure	106
Tris-buffered saline (TBS)	293
Trypan blue dye exclusion test	183–184
Tumor amplified protein expression	
therapy-cytosine deaminase (TAPET-CD),	
<i>Salmonella typhimurium</i>	
antitumor activity	656–657
¹⁴ C-5-Fluorocytosine (FC) and	
¹⁴ C-5-Fluorouracil (FU)	657
quantitation	656
VNP20029 derivation	653
Tumor-associated antigens (TAAs)	33, 167
Tumor cell apoptosis induction, TRAIL	
gene therapy	
adenovirus production	317–318
Ad5-mTRAIL transgene expression	
mTRAIL protein production	328
purification	322
verification	327–328
cell culture, PCR and cloning	317
cell lines growth	319
flow cytometry	318
HEK 293 transfection	320–322
mTRAIL gene encoding	319–320
murine gene cloning	320
SDS-PAGE and immunoblotting	318
viral particle purification	
CsCl gradient centrifugation	323
dialysis	323–324
glycerol stock and target values	324
viral titer quantitation	
A549 overlays schedule	326–327
dilution preparation	325–326
results	327
<i>in vitro</i> killing method	
adenoviral vectors	329–331
recombinant adenovirus	319
Tumor infiltrating lymphocytes (TILs)	7, 502, 503
Tumor necrosis factor	315
Tumor necrosis factor-related apoptosis-inducing	
ligand (TRAIL)	28
Tumor neutralization assay, ATV-NDV	586
Tumor-specific antigens (TSAs)	33
Tumor-targeting bacteria (TTBac)	132–134, 138, 140,
143–144, 146–149	
U	
Ultrasound-mediated gene transfection	
advantages	190–191
cell culture	181–182
cell viability measurement	183–184
description	181
fluorescence microscopy and flow cytometry	185
luciferase assay	184–185
sonotransfection	
<i>in vitro</i>	185–187
<i>in vivo</i>	189–190
<i>in vivo</i> -simulated <i>in vitro</i>	187–189
therapy and bioeffects	180
ultrasound apparatus and intensity	
measurement	182–183
V	
Vascular endothelial growth factor	
(VEGF)	32, 137, 138, 288, 364
Viral delivery systems	
adenoviral vectors	
advantages and gene delivery	12–13
and structure	11
structure improvement	13–14
transcriptional units	12
herpes simplex vectors (HSV)	19–20
lentiviral vectors	
advantages	18–19
neurological disorders	17–18
types	17
retroviral vectors	
advantages	14–15
characteristics	14
disadvantages	15

modifications	16
replication-competent.....	16–17
replication-defective	15–16
therapy types.....	15
simian virus 40 (SV40)	
characteristics and advantages.....	22
description	20–21
Viral oncolytic therapy	438
Viral production	
AAVs.....	449–450
adenoviruses.....	449
animal cells, <i>in vitro</i> cultures.....	447
buffers.....	452
cell culture and viral propagation.....	452
cell inoculum and bioreaction.....	456–457
recombinant baculovirus stock.....	456
viral replication	455
chromatography and membrane	
processes	451–452
downstream processing.....	453–454
anion-exchange chromatography.....	460
depth-filter system.....	458
harvest/clarification	457–458
liquid chromatography system	459
recombinant baculoviruses, desalting.....	460–461
ultrafiltration/diafiltration	458–459
issues and challenges.....	451
recombinant baculoviruses.....	450
characterization	454–455, 464–467
immunoblot	466
quantitation	454, 461–464
retroviruses and.....	448–449
viral vector preparations.....	448
Viral shuttle vector	
Fcy::Fur gene cloning	559
GALV <i>env</i> R-gene cloning	558–559
Virus directed enzyme prodrug therapy	
(VDEPT)	134
VNP20009, <i>Salmonella typhimurium</i>	136–138,
142, 143, 145, 147–149	
W	
Wheat germ agglutinin (WGA)	290
Woodchuck Hepatitis Virus (WPRE)	120
World Health Organisation (WHO)	538
X	
X-linked severe combined immunodeficiency	
(X-SCID)	545, 546